Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07680166 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Xentria, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modifiedv2 Show 4 more changesShow less
    • Phase changed: Phase 1/2 → Phase 2
    • Secondary endpoints: 3 to 19
    • Study description shortened, about 4 words
    • Study title shortened, about 4 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Xentria, Inc.
6 trials monitored
See 3 trials at risk
A study of XTMAB-16 in patients with pulmonary sarcoidosis
Trial Details
NCT Number NCT07680166
Lead Sponsor Xentria, Inc.
Conditions
(from sponsor)		 Pulmonary Sarcoidosis
Related terms Sarcoidosis, Pulmonary
Enrollment 182 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov